source
- Novo signs development deal with Swedish biotech Nanexa to license long-acting delivery technologyNovo Nordisk has entered a new development agreement with the Swedish biotech Nanexa. Under the pact, Nanexa will license its long-acting drug delivery platform to Novo, expanding the larger compa…
- Legend's five-year data suggests Carvykti could be a cure; Addex, Indivior splitPlus news about Amberstone, Henlius and Boehringer Ingelheim. Legend adds to argument for Carvykti as a cure: J&J and Legend Biotech said Friday that 10 of 20 relapsed/refractory multiple myeloma p…